セッション詳細
[F1]Flash Talks (1)
2025年10月21日(火) 13:40 〜 13:58
FORESTHALL A(LINK FOREST 1F)
Chair:Jun-ichiro Inoue
[F1-01]Generation of a site-specific transcription factor blocker as a versatile TF inhibitor
*Hideo Negishi1,2,3,4, Tatsuma Ban5, Mina Kurosawa1, Shonrod Airisshu1, Yusuke Wada1, Tomoya Hayashi1,2,4, Kaiwen Liu1,2,4, Yoshitaka Shirasaki6, Temizoz Burcu1,2,4, Kouji Kobiyama1,2,4, Noriko Toyama-Sorimachi2, Cevayir Coban2,4,7, Tomohiko Tamura5, Tomio Iwasaki8, Ken J Ishii1,2,4,9,10 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 2. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 3. Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan. (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan. (Japan), 5. Department of Immunology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan. (Japan), 6. Division of Photonic Imaging, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. (Japan), 7. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 8. Research and Development Group, Hitachi, Ltd., Ibaraki, Japan. (Japan), 9. Laboratory of Vaccine Science, Immunology Frontier Research Center (IFReC), Osaka University, Osaka, Japan. (Japan), 10. Laboratory of Mockup Vaccine, Center for Vaccine and Adjuvant Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan. (Japan))
[F1-02]Development of a Novel Therapeutic Strategy for the Elimination of Hepatitis B Virus DNA Using CRISPR-Cas3
*Yoshiki Saiki1, Kazuto Yoshimi1, Masahiko Ito2, Tetsuro Suzuki2, Yumi Kanegae1, Tomoji Mashimo1 (1. Division of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science , The University of Tokyo (Japan), 2. Department of Microbiology and Immunology, Hamamatsu University School of Me dicine (Japan))
[F1-03]Cell Type-Dependent Genetic Stability of EGFP in Recombinant HCoV-229E
*Aikeda Aishajiang1, Yuki Kitai1, Shohei Kojima2, Rina Hashimoto3, Miyuki Kawase4, Hiroshi Katoh1, Kazuya Shirato4, Kazuo Takayama3, Makoto Takeda1 (1. Graduate School of Medicine, The University of Tokyo (Japan), 2. Human Biology-Microbiome-Quantum Research Center, Keio University (Japan), 3. Medical Research Institute, Institute of Integrated Research, Institute of Science, Tokyo (Japan), 4. National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))
[F1-04]Vaccine delivery technology using bacterial extracellular vesicles
*Aya Ishizaka1, Taketoshi Mizutani2, Michiko Koga1,3, Hiroshi Yotsuyanagi1,4 (1. The Institute of Medical Science, The University of Tokyo (Japan), 2. National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center, the University of Tokyo (Japan), 4. Japan Institute for Health Security (Japan))
[F1-05]Human monoclonal antibodies elicited by influenza H3 HA antigen with ‘scrambled’ immunodominant epitopes target conserved loci to exert protective effects in vivo
*Shiho Chiba1,2, Gabriele Neumann2, Yoshihiro Kawaoka1,2,3 (1. The University of Tokyo (Japan), 2. University of Wisconsin-Madison (United States of America), 3. International Virus Infectious Disease Research Center, Japan Institute for Health Security (Japan))
[F1-06]Human Monoclonal Antibodies Exhibit Two Distinct Neutralization Patterns Against H3N2 Influenza
*Calvin Duong1,4, Yui Honjo1, Mifuki Goto1, Jisuk Ko1, David Pattinson5, Lavanya Babujee5, Gabriele Neumann5, Seiya Yamayoshi1,2,3,4, Yoshihiro Kawaoka1,3,4,5 (1. Division of Virology, Institute of Medical Science, University of Tokyo, Japan (Japan), 2. International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo (Japan), 3. Research Center for Global Viral Infections, National Center for Global Health and Medicine Research Institute (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (Japan), 5. Department of Pathobiological Sciences, School of Veterinary Medicine (United States of America))
[F1-07]Identification of a broadly neutralizing antibody against the SARS-CoV-2 Spike S2 domain.
*Mizuki Yamamoto1, Yoko Hirayama1, Jun-ichiro Inoue2, Yasushi Kawaguchi1,2,3, Xuenan Xuan1 (1. Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo (Japan), 2. The University of Tokyo Pandemic preparedness, Infection and Advanced research center (UTOPIA), The University of Tokyo (Japan), 3. Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan))
[F1-08]Generation of recombinant bovine coronavirus expressing a reporter using the BAC system
*関根 渉1 (1. Department of Veterinary Medical Science, The University of Tokyo (Japan))
[F1-10]Profiling of neutrophils predicts the survival fate upon lethal viral infection
*Riho Saito1,2, Hiroki Sugishita1, Yukiko Gotoh1, Tomohiko Okazaki2 (1. The University of Tokyo (Japan), 2. Hokkaido University (Japan))
[F1-11]Insights into antigen reactivity of ThA cells in systemic lupus erythematosus through scRNA-seq analysis
*Hiroyuki Teruya1, Toshiyuki Ushijima1, Manaka Goto1,2, Hideyuki Takahashi1, Takahiro Itamiya1,2, Hirofumi Shoda3, Haruka Tsuchiya1, Mineto Ota1, Tomohisa Okamura1,2, Keishi Fujio1 (1. Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo (Japan), 2. Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo (Japan), 3. Department of Rheumatology, Tokyo Medical University Hospital (Japan))
[F1-12]Cross-species reactive IgA targets physicochemical pattern of pathogenic bacteria
*Genta Furuya1, Fumihito Usui2, Keishu Takahashi1, Satoru Nagatoishi3, Rae Maeda4, Ryutaro Tamano1, Tomoya Ohno1, Kengo Sasaki1, Naoki Morita1, Peng Gao1, Fabian Eisenstein5, Hirofumi Kosuge3, Masumi Shirakawa6, Hiroyuki Arai7, Radostin Danev5, Hirotada Mori8, Masahide Kikkawa5, Shinsuke Sando6, Naoshi Dohmae9, Toshio Hakoshima10, Yuki Sugiura4, Kohei Tsumoto3, Reiko Shinkura1 (1. Institute for Quantitative Biosciences, The University of Tokyo (Japan), 2. Applied Immunology, Graduate School of Science and Technology, Nara Institute of Science and Technology (Japan), 3. Department of Bioengineering, School of Engineering, The University of Tokyo (Japan), 4. Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine (Japan), 5. Department of Cell Biology and Anatomy, Graduate School of Medicine, The University of Tokyo (Japan), 6. Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo (Japan), 7. Department of Biotechnology, Graduate School of Agricultural and Life Sciences, The University of Tokyo (Japan), 8. Innovation Laboratory of Systems Microbiology and Synthetic Biology, Institute of Animal Sciences, Guangdong Academy of Agricultural Sciences (Japan), 9. Biomolecular Characterization Unit, RIKEN Center for Sustainable Resource Science (Japan), 10. Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology (Japan))
[F1-13]Biphasic innate immune cell-mediated memory responses confer protection against viral infection
*Asuka Joy Tobuse1, Kouji Kobiyama1,2,3, Jun Tsuchida1, Teppei Hara1, Masamitsu Asaka4, Daichi Utsumi4, Yaeko Nakajima-Takagi5, Motohiko Oshima5, Tomoya Hayashi1, Burcu Temizoz1, Yasuhiro Yasutomi4, Atsushi Iwama5, Ken J Ishii1,2 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 2. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 3. Division of Rheumatology, Department of medicine, University of California San Diego, La Jolla (United States of America), 4. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan), 5. Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan (Japan))
[F1-14]An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics
Yayoi Natsume Kitatani1,2,3, Kouji Kobiyama4,5,6, Yoshinobu Igarashi7, Taiki Aoshi8, Noriyuki Nakatsu7, Lokesh P Tripathi1,9, Junichi Ito10, Johan Nystrom Persson11, Yuji Kosugi12, Rodolfo S. Allendes Osorio13, Chioko Nagao3, *Burcu Temizoz4,5, Etsushi Kuroda14, Daron M. Standley15, Hiroshi Kiyono16,17,18, Kenji Nakanishi14, Satoshi Uematsu19,20, Isao Hamaguchi21, Yasuhiro Yasutomi22, Jun Kunisawa23, Sho Yamasaki24,25,26,27, Cevayir Coban5,28,29,30, Hiroshi Yamada7, Kenji Mizuguchi3, Ken J Ishii4,5,29,30 (1. Laboratory of Bioinformatics, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Settsu, Osaka (Japan), 2. Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Tokushima 770-8503, Japan (Japan), 3. Institute for Protein Research, the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 4. Laboratory of Vaccine Science, the Institute of Medical Science, the University of Tokyo (IMSUT), Minato-ku, Tokyo 108-8639, Japan (Japan), 5. International Vaccine Design Center (VDesC), the Institute of Medical Science, the University of Tokyo (IMSUT), Minato-ku, Tokyo 108-8639, Japan (Japan), 6. Division of Rheumatology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093-0809, USA (United States of America), 7. Toxicogenomics-Informatics Project, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Settsu, Osaka (Japan), 8. Department of Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan (Japan), 9. RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan (Japan), 10. Discovery Concept Validation Function, Eisai Co., Ltd., Kobe, Hyogo 650-0047, Japan (Japan), 11. JNP Solutions, Sumida-ku, Tokyo 130-0015, Japan (Japan), 12. Lifematics Ltd., Chuo-ku, Tokyo 104-0032, Japan (Japan), 13. Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 14. Department of Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo 663-8501, Japan (Japan), 15. Department of Genome Informatics, Genome Information Research Center, Research Institute for Microbial Diseases (RIMD), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 16. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba 260-8670, Japan (Japan), 17. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, Chiba, Chiba 260-8670, Japan (Japan), 18. CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine, San Diego, CA 92093-0063, USA (United States of America), 19. Department of Immunology and Genomics, Graduate School of Medicine, Osaka Metropolitan University, Abeno, Osaka 545-0051, Japan (Japan), 20. Division of Metagenome Medicine, Human Genome Center, the Institute of Medical Science, the University of Tokyo, Minato-ku, Tokyo 108-8639, Japan (Japan), 21. Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan (Japan), 22. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Tsukuba, Ibaraki 305-0843, Japan (Japan), 23. Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Ibaraki, Osaka 567-0085, Japan (Japan), 24. Department of Molecular Immunology, Research Institute for Microbial Diseases (RIMD), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 25. Laboratory of Molecular Immunology, Immunology Frontier Research Center (IFReC), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 26. Center for Infectious Disease Education and Research (CiDER), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 27. Center for Advanced Modalities and DDS (CAMaD), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 28. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), the University of Tokyo, Tokyo 108-8639, Japan (Japan), 29. WPI Immunology Frontier Research Center (IFReC), the University of Osaka, Suita, Osaka 565-0871, Japan (Japan), 30. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), the University of Tokyo, Tokyo 108-8639, Japan (Japan))
[F1-15]Spatial and Clonal Dynamics of B Cells in Cancer Tissue Revealed by Integrated BCR and Transcriptomic Profiling
*Tomomi Namiki1, Mikiya Takata1, Ayumu Tsubosaka1, Kyohei Sano1, Miwako Kakiuchi1, Daisuke Komura1, Hiroto Katoh3, Tetsuo Ushiku2, Shumpei Ishikawa1 (1. Graduate School of Medicine, The University of Tokyo (Japan), 2. Department of Pathology, Graduate School of Medicine, The University of Tokyo (Japan), 3. Division of Pathology, National Cancer Center Exploratory Oncology Research & Clinical Trial Center (Japan))
[F1-16]Integrative Optimization of TLR9 and STING Agonist-Based Strategies in Cancer Immunotherapy
*Mai Onaga1, Burcu Temizoz1, Seigo Akaeda2, Kou Hioki3, Kaiwen Liu1, Tomoya Hayashi1, Hideo Negishi1, Kouji Kobiyama4, Peter D. Katsikis3, Cevayir Coban1, Ken J Ishii1 (1. The University of Tokyo (Japan), 2. Yokohama City University (Japan), 3. Erasmus University Medical Center (Netherlands), 4. University of California San Diego (United States of America))
[F1-17]Construction and evaluation of novel AAV vector vaccines aimed at effective immune induction
*Ken Sugo1, Hiroshi Ueki2,3,4, Yuji Tsunekawa1, Emiko Urano5, Yukage Kobari1, Yasunari Matsuzaka1, Koji Kobiyama6, Guillermo Posadas-Herrera1, Hiromi Hayashita-Kinoh1, Mikako Wada1, Yukihiko Hirai1, Yasushi Soda1, Yasuhiro Yasutomi7,8,9, Ken J. Ishii6,10,11,12,13, Seiya Yamayoshi2,3,4, Yoshihiro Kawaoka2,3,4, Takashi Okada1 (1. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo (Japan), 2. Division of Virology, The Institute of Medical Science, The University of Tokyo (Japan), 3. Center for Global Viral Diseases, National Institute of Global Health and Medicine (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) (Japan), 5. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) (Japan), 6. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 7. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) (Japan), 8. School of Integrative and Global Majors, University of Tsukuba (Japan), 9. Department of Immunoregulation, Mie University Graduate School of Medicine (Japan), 10. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 11. Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (Japan), 12. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 13. Laboratory of Vaccine Science, Immunology Frontier Research Center, The University of Osaka (Japan))
[F1-18]Development of novel arrowhead-shaped microneedle array device for COVID-19 vaccination using recombinant vaccinia virus vectors
Kotaro Shobayashi1, *Jongho Park2, Hoshimi Aoyagi2, Fumihiko Yasui3, Michinori Kohara3, Beomjoon Kim2 (1. Department of Precision Engineering, School of Engineering, The University of Tokyo (Japan), 2. Institute of Industrial Science, The University of Tokyo (Japan), 3. Tokyo Metropolitan Institute of Medical Science (Japan))